Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907332 | 0.92 | TAAR1 (0.81) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL3760581 | 0.92 | TAAR1 (0.75) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL3206286 | 0.91 | GRIN2B (0.65) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL3206279 | 0.91 | GRIN2B (0.65) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL14934759 | 0.91 | GRIN2B (0.65) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL25002632 | 0.90 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL3665298 | 0.90 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL24075499 | 0.90 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL22216853 | 0.90 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 | |
| SCHEMBL21792273 | 0.90 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| CN-108689951-A | 3-triazole compounds and its application in agricultural | 东莞东阳光科研发有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004105762-A1 | MEDICAL USE OF DIAZABICYCLONONENE DERIVATIVES AS INHIBITORS OF PARASITE ASPARTIC PROTEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | GRIN2B 3003/4885TAAR1 2754/4885SIGMAR1 4561/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | GRIN2B 3006/4885TAAR1 1785/4885SIGMAR1 3209/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | GRIN2B 3161/4885TAAR1 3031/4885SIGMAR1 4395/4885 |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | GRIN2B 736/4885TAAR1 1467/4885SIGMAR1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.